Drugs / NVR 3-778
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02401737 | Jan 2015 → May 2016 | chronic hepatitis B virus infection | Novira Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02112799 | Apr 2014 → May 2016 | chronic hepatitis B virus infection | Novira Therapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NVR 3-778 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02112799 ↗ |
| Action | Inhibit | “can inhibit HBV replication” PMID 30625297 ↗ Jan 2019 |
| Route | Oral | “patients were randomly assigned to groups that were given oral NVR 3-778” PMID 30625297 ↗ Jan 2019 |